The diagnostic problem in children is fundamentally different from the problem in adults. Young children often cannot produce sputum, their clinical presentations overlap with common childhood illnesses such as pneumonia, and microbiological confirmation rates remain low even in well-resourced centers. Access to appropriate testing is also uneven across settings, which means a technique that works in a specialist hospital may be unavailable where most pediatric tuberculosis cases actually occur. Zhang’s editorial frames this as the gap between technical promise and clinical usefulness: a test that performs well in a selected research population may not retain that performance across different ages, disease presentations, or healthcare environments. Research, the argument goes, should be judged not only on diagnostic accuracy but on specimen feasibility, affordability, turnaround time, and whether a positive result actually leads to earlier treatment.

The narrative review by Yang and colleagues, cited in the editorial, examines recent developments across three fronts: molecular diagnostics applied to non-sputum specimens, host-response biomarkers, and artificial intelligence-assisted imaging. Molecular testing of samples such as gastric aspirates, stool, or nasopharyngeal specimens offers a way around the sampling barriers that have long hampered pediatric confirmation. But the newer biomarkers and imaging algorithms still require robust validation in pediatric populations before they can be trusted broadly. The editorial stresses that the key question is not whether a test is novel, but whether it changes management and improves outcomes. That framing pushes the field away from chasing sensitivity and specificity figures in isolation and toward measuring downstream effects: time to treatment, appropriateness of therapy, and ultimately survival and morbidity.

Imaging illustrates both the promise and the peril of pattern recognition. Wang and colleagues report a retrospective cohort of 63 children in which a model combining multiple pulmonary nodules with lymphadenopathy showed striking discrimination between pulmonary tuberculosis and pneumonia, with a reported area under the receiver operating characteristic curve of 0.99. Those numbers demand caution. The cohort came from a small, select population at a specialist hospital and included only 15 pneumonia controls, so the near-perfect estimate could easily shrink under independent prospective validation. The editorial is explicit that the model’s present contribution is to inform integrated clinical assessment, not to establish computed tomography as a standalone diagnostic tool or a routine screening strategy. In other words, imaging clues are inputs to clinical reasoning, not replacements for it.

Two case reports show what happens when diagnostic uncertainty meets unusually severe disease. Li and colleagues describe infantile endobronchial tuberculosis complicated by Pneumocystis jirovecii coinfection in a child carrying an IKZF1 variant associated with immune dysfunction. Serial bronchoscopic assessments documented necrotizing airway disease and progressive stenosis, and the child improved after combined systemic therapy and bronchoscopic interventions. The case underscores the importance of considering airway complications and underlying immune abnormalities when an infant presents with disease far more severe than expected. Yet the editorial is careful about what the report cannot establish: the favorable outcome cannot isolate the contribution of intraluminal drug administration, nor prove that it prevents permanent stenosis. That question requires comparative evidence, not a single success story.

The second case report is a study in how incomplete early pictures can mislead. Contreras-Rojas and colleagues describe a toddler with tuberculous meningitis whose cerebral infarcts appeared before the classic basilar enhancement and hydrocephalus that clinicians are taught to expect. Serial imaging documented substantial progression over just four days, despite initially normal large-vessel angiography and a normal chest radiograph. The lesson, according to the editorial, is that an incomplete early radiological picture does not exclude severe disease; cerebrospinal fluid findings, epidemiological history, neurological examination, and evolving imaging must be weighed together. Management in the case combined antituberculosis treatment, corticosteroids, cerebrospinal fluid diversion, and rehabilitation, illustrating that care for neurological tuberculosis extends well beyond antimicrobial prescribing into coordinated, multidisciplinary territory.

Placed side by side, the imaging cohort and the meningitis case form an instructive contrast. Recognizable patterns may help distinguish disease in one selected population, while the early absence of those same patterns can be dangerously misleading in a different clinical setting. The editorial draws the technical conclusion directly: the value of imaging depends not merely on the feature detected, but on the disease site, the timing of the scan, and the population in which the image is interpreted. This is a recurring theme in pediatric tuberculosis research, where findings from referral centers with high disease prevalence may not transfer to primary care settings where the same symptoms are far more likely to be something else entirely.

The research topic also reaches beyond tuberculosis strictly defined. Ruan and colleagues present a five-patient series of nontuberculous mycobacterial disease, an important differential diagnosis rather than a form of tuberculosis itself. The cases included Mycobacterium abscessus and Mycobacterium paragordonae infections at different anatomical sites and in different host conditions, ranging from structural airway disease and cystic fibrosis to DiGeorge syndrome. Species-level identification proved decisive, because clinically similar presentations required different management. Targeted sequencing was useful in selected cases, though the series could not establish comparative diagnostic accuracy or treatment superiority. The editorial emphasizes that molecular findings must be interpreted alongside clinical, imaging, histopathological, and other microbiological evidence, and that both pathogen identity and host defenses matter when an apparent mycobacterial infection follows an atypical course.

Prevention gets its own case study in the work of Tang and colleagues, who investigated a tuberculosis outbreak in a vocational school. Repeated contact screening, classroom and dormitory assessments, and whole-genome sequencing provided complementary information about the transmission cluster. Genomic relatedness supported the epidemiological investigation, but the editorial cautions that it should not be equated with proof of every transmission link or its direction. Just as important, the investigation documented real barriers to preventive treatment, including concerns among students, families, and clinicians about taking medication when they felt well. Identifying infection, the editorial argues, is only one step; prevention depends on appropriate assessment, honest communication, treatment uptake, and sustained follow-up, all of which require clinical services to connect with schools and public health teams alongside ventilation improvements and early recognition of illness.

What the collection leaves unanswered is as telling as what it delivers. None of the contributions provide a comparative evaluation of pediatric tuberculosis regimens or drug exposure, and the editorial notes that the clinical reports instead show why disease site, organ complications, host factors, and the feasibility of follow-up deserve attention alongside antimicrobial selection. Children with airway disease or neurological complications need coordinated specialist care, while adolescents offered preventive treatment need a credible explanation of benefits and harms. The proposed research agenda asks for validation of diagnostic approaches in diverse pediatric populations, inclusion of children with complex comorbidities, and measurement of effects on treatment decisions and outcomes, plus longer-term respiratory and neurological follow-up and safety assessment. Implementation studies should trace where children and families are lost between testing, treatment initiation, and completion. The next real advance, the editorial concludes, will arrive when diagnostic innovation and clinical vigilance are matched by reliable access to care, so that earlier recognition and appropriate interpretation of evidence translate into sustained linkage to treatment and prevention for every child.

Subject of Research: Advances in diagnosis, treatment, and management of tuberculosis in children

Article Title: Editorial: Advances in tuberculosis in children: diagnosis, treatment, and management strategies

Article References: Zhang, P. (2026). Editorial: Advances in tuberculosis in children: diagnosis, treatment, and management strategies. Frontiers in Pediatrics, 14, Article 2009297. https://doi.org/10.3389/fped.2026.2009297

Image Credits: AI Generated

DOI: 10.3389/fped.2026.2009297

Keywords: pediatric tuberculosis, tuberculous meningitis, nontuberculous mycobacteria, molecular diagnostics, host-response biomarkers, AI-assisted imaging, endobronchial tuberculosis, preventive treatment, outbreak investigation, whole-genome sequencing, diagnostic uncertainty, childhood pneumonia